What do recent observations reveal about the "blind date" with Lp(a)-reducing drugs?

Affiliations

Editorial

Florian Kronenberg. Eur J Prev Cardiol. 2025.

. 2025 Jun 3:zwaf324.

doi: 10.1093/eurjpc/zwaf324. Online ahead of print.

¹ Institute of Genetic Epidemiology; Medical University of Innsbruck, Innsbruck, Austria.

No abstract available

Comment on

Impact of evolocumab on plaque phenotypic changes in patients with acute coronary syndrome and elevated lipoprotein(a) levels: a HUYGENS secondary analysis.
Di Giovanni G, Fujino M, Kataoka Y, Butters J, Hucko T, Puri R, Nissen SE, Nelson AJ, Psaltis PJ, Nicholls SJ. Di Giovanni G, et al. Eur J Prev Cardiol. 2025 Apr 8:zwaf211. doi: 10.1093/eurjpc/zwaf211. Online ahead of print. Eur J Prev Cardiol. 2025. PMID: 40424182